Radiation plus immunotherapy: a new hope for melanoma?
NCT ID NCT01416831
First seen May 07, 2026 · Last updated May 07, 2026
Summary
This study looked at whether adding targeted radiation (SBRT) to high-dose Interleukin-2 (IL-2) therapy could shrink tumors better than IL-2 alone in people with metastatic melanoma. 44 adults with tumors that could be safely radiated took part. The goal was to compare overall response rates between the two groups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Providence Cancer Center
Portland, Oregon, 97213, United States
Conditions
Explore the condition pages connected to this study.